News
FDA okays first generics for Eliquis
“These approvals mark the first generic approvals of a direct oral anticoagulant.”
News
End-stage renal disease risk in lupus nephritis remains unchanged of late
Key clinical point: The risk of end-stage renal disease in lupus nephritis decreased from the 1970s to the mid-1990s but has since remained...
News
Wearable device offers home-based knee OA pain relief
Key clinical point: Pulsed electromagnetic fields therapy is safe and effective in improving knee osteoarthritis symptoms. Major finding: The mean...
News
Metformin trims mother’s weight, but not baby’s
In obese pregnant women without diabetes, daily metformin reduces maternal weight gain, but not infant birth weight, results of the MOP trial show...
News
Office visits still common before colonoscopy
Nearly 30% of outpatient colonoscopies for colon cancer screening or polyp surveillance were preceded by a gastroenterology office visit, with...
News
Minimal residual disease a powerful prognostic factor in AML
Key clinical point: The presence of minimal residual disease provides powerful prognostic information independent of other risk factors in...
News
Research refining radiomic features for lung cancer screening
Key clinical point: Non-invasive radiomics is showing potential for reducing false positives by differentiating between benign and cancerous lung...
News
Lymphedema microsurgery gaining momentum
Advances in microsurgery technique have made lymphovenous bypass (LVB) and lymph node transfer (LNT) increasingly feasible as treatment for...
News
Making sense of the expanded myeloma treatment landscape
Experts at the FDA/ASH symposium shed light on use of the three newly approved agents daratumumab, ixazomib, and elotuzumab.